norfloxacin has been researched along with Infections, Pseudomonas in 39 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 9.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 9.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "Studies on a combination therapy of fosfomycin (FOM) and norfloxacin (NFLX) against chronic otitis media were performed, and the following results were obtained." | 7.70 | [Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media]. ( Uno, Y, 1999) |
| "We treated 15 men who had chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin with 400 mg." | 7.68 | The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. ( Darras, FS; Schaeffer, AJ, 1990) |
| " In this study, silver norfloxacin appears to be the most effective antibiotic against P aeruginosa corneal ulcer in the rabbit." | 7.67 | Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit. ( Darrell, RW; Fox, CL; Modak, SM, 1984) |
| "were treated with norfloxacin and 16 (84%) responded to therapy." | 5.27 | The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. ( Emmanuel, FX; Leigh, DA, 1984) |
| "The efficacy and safety of a 5-day course of treatment with the new oral penem agent ritipenem acoxil (500 mg three times daily) or with norfloxacin (200 mg twice daily) were assessed in a double-blind study of women with uncomplicated cystitis." | 5.08 | Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group. ( , 1995) |
| " The treatment of 37 initial febrile episodes (12 cases of septicemia, 7 infectious sites and 38 cases of fever of unknown origin) in 33 neutropenic patients (PMN leucocytes less than 500/mm3) using the combination of a third generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacin) resulted in an 86% immediate success rate (32 cases/37)." | 5.06 | [Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)]. ( Bielefeld, P; Caillot, D; Guy, H; Kazmierczak, A; Portier, H; Solary, E, 1987) |
| "Respiratory tract infections were treated with pefloxacin in fifteen patients, who were hospitalized in the intensive care unit and required artificial ventilation." | 5.06 | Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit. ( Boland, DM; de Jong, D; MacLaren, DM; van Gestel, WC, 1987) |
| "Studies on a combination therapy of fosfomycin (FOM) and norfloxacin (NFLX) against chronic otitis media were performed, and the following results were obtained." | 3.70 | [Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media]. ( Uno, Y, 1999) |
| "Twelve elderly diabetic patients with Pseudomonas otitis externa malignum were successfully treated with norfloxacin as monotherapy for 2-5 weeks, using 400 mg b." | 3.68 | Otitis externa malignum. ( Sabbour, MS, 1991) |
| "We treated 15 men who had chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin with 400 mg." | 3.68 | The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin. ( Darras, FS; Schaeffer, AJ, 1990) |
| " In this study, silver norfloxacin appears to be the most effective antibiotic against P aeruginosa corneal ulcer in the rabbit." | 3.67 | Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit. ( Darrell, RW; Fox, CL; Modak, SM, 1984) |
| "Twenty-four patients with complicated urinary tract infections were treated with norfloxacin for three months." | 3.67 | Norfloxacin treatment in complicated urinary tract infection. ( Boerema, JB; van Saene, HK, 1986) |
| "Feline otitis externa is a dermatological disorder with a multifactorial complex etiology." | 1.62 | Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya. ( Altaeb, AA; Bennour, EM; Duro, EM; Ellraiss, OM; Elmishri, RA; Hiblu, MA; Karim, ES, 2021) |
| "Clinafloxacin was more active than ciprofloxacin, norfloxacin and pefloxacin, independent to the sensitivity pattern or the resistance to ceptazidime and imipenem." | 1.31 | [The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem]. ( Chaves, J; del Carmen Conejo, M; Hernández, G; Joyanes, P; Martínez-Martínez, L; Pascual A, A; Perea, EJ, 2001) |
| "Norfloxacin nicotinate was injected intramuscularly into the bull at 5 mg/kg daily for 7 days." | 1.29 | Norfloxacin nicotinate in the treatment of Pseudomonas aeruginosa infection in the genital tract of a bull. ( Bernstein, M; Gipps, M; Glickman, A; Marcus, S; Ziv, G, 1994) |
| "Norfloxacin was the most active antimicrobial agent tested against all isolates studied; it was the only agent active against P." | 1.27 | Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance. ( Appleman, MD; Corigliano, BE; Heseltine, PN; Leedom, JM, 1984) |
| "were treated with norfloxacin and 16 (84%) responded to therapy." | 1.27 | The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin. ( Emmanuel, FX; Leigh, DA, 1984) |
| " This risk may depend on the dosing schedule and may be reduced by combined therapy." | 1.27 | Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. ( Auckenthaler, R; Michéa-Hamzehpour, M; Pechère, JC; Regamey, P, 1987) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| "Pefloxacin was given as the single drug (except in one case) to twenty-seven patients with a variety of infections (bone and/or joint: 8; respiratory tract: 6; urinary tract: 5; bacteremia: 4; meninges: 3; other: 1)." | 1.27 | [Pefloxacin: clinical experience]. ( Bertrand, A; Janbon, F; Jonquet, O; Jourdan, J; Santoni, A, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (51.28) | 18.7374 |
| 1990's | 12 (30.77) | 18.2507 |
| 2000's | 4 (10.26) | 29.6817 |
| 2010's | 1 (2.56) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Reinhardt, A | 1 |
| Köhler, T | 1 |
| Wood, P | 1 |
| Rohner, P | 1 |
| Dumas, JL | 1 |
| Ricou, B | 1 |
| van Delden, C | 1 |
| Khalil, H | 1 |
| Chen, T | 1 |
| Riffon, R | 1 |
| Wang, R | 1 |
| Wang, Z | 1 |
| Pratap Verma, D | 1 |
| Ansari, MM | 1 |
| Verma, NK | 1 |
| Saroj, J | 1 |
| Akhtar, S | 1 |
| Pant, G | 1 |
| Mitra, K | 1 |
| Singh, BN | 1 |
| Ghosh, JK | 1 |
| Hiblu, MA | 1 |
| Ellraiss, OM | 1 |
| Karim, ES | 1 |
| Elmishri, RA | 1 |
| Duro, EM | 1 |
| Altaeb, AA | 1 |
| Bennour, EM | 1 |
| James, CE | 1 |
| Fothergill, JL | 1 |
| Hall, AJ | 1 |
| Cottell, J | 1 |
| Brockhurst, MA | 1 |
| Winstanley, C | 1 |
| Corigliano, BE | 1 |
| Appleman, MD | 1 |
| Heseltine, PN | 1 |
| Leedom, JM | 1 |
| Leigh, DA | 1 |
| Emmanuel, FX | 1 |
| Darrell, RW | 1 |
| Modak, SM | 2 |
| Fox, CL | 2 |
| Marcus, S | 1 |
| Bernstein, M | 1 |
| Ziv, G | 1 |
| Glickman, A | 1 |
| Gipps, M | 1 |
| Reid, G | 1 |
| Sharma, S | 1 |
| Advikolanu, K | 1 |
| Tieszer, C | 1 |
| Martin, RA | 1 |
| Bruce, AW | 1 |
| Huo, ZL | 1 |
| Uno, Y | 1 |
| Jalal, S | 1 |
| Ciofu, O | 1 |
| Hoiby, N | 1 |
| Gotoh, N | 1 |
| Wretlind, B | 1 |
| Pascual A, A | 1 |
| Joyanes, P | 1 |
| Martínez-Martínez, L | 1 |
| del Carmen Conejo, M | 1 |
| Hernández, G | 1 |
| Chaves, J | 1 |
| Perea, EJ | 1 |
| Aubert, G | 1 |
| Pozzetto, B | 1 |
| Dorche, G | 1 |
| Ravaoarinoro, M | 1 |
| Toma, E | 1 |
| Fallara, A | 1 |
| Huber-Spitzy, V | 1 |
| Baumgartner, I | 1 |
| Arocker-Mettinger, E | 1 |
| Schiffbänker, M | 1 |
| Georgiew, L | 1 |
| Grabner, G | 1 |
| Reidy, JJ | 1 |
| Hobden, JA | 1 |
| Hill, JM | 1 |
| Forman, K | 1 |
| O'Callaghan, RJ | 1 |
| Sabbour, MS | 1 |
| Vajpayee, RB | 1 |
| Gupta, SK | 1 |
| Angra, SK | 1 |
| Munjal, A | 1 |
| Schaeffer, AJ | 1 |
| Darras, FS | 1 |
| Chamberland, S | 1 |
| Bayer, AS | 2 |
| Schollaardt, T | 1 |
| Wong, SA | 1 |
| Bryan, LE | 1 |
| Davies, BI | 1 |
| Maesen, FP | 1 |
| Teengs, JP | 1 |
| Baur, C | 1 |
| Boerema, JB | 2 |
| Guy, H | 1 |
| Caillot, D | 1 |
| Solary, E | 1 |
| Bielefeld, P | 1 |
| Portier, H | 1 |
| Kazmierczak, A | 1 |
| Michéa-Hamzehpour, M | 2 |
| Pechère, JC | 2 |
| Marchou, B | 1 |
| Auckenthaler, R | 2 |
| Regamey, P | 1 |
| Hirano, L | 1 |
| Yih, J | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Rowen, RC | 1 |
| Mullenix, TA | 1 |
| Arroyo, JC | 1 |
| Voris, JC | 1 |
| Ge, SD | 1 |
| Boland, DM | 1 |
| van Gestel, WC | 1 |
| MacLaren, DM | 1 |
| de Jong, D | 1 |
| Thomas, JM | 1 |
| Swanson, NA | 1 |
| van Saene, HK | 1 |
| Fernandes, PB | 1 |
| Chu, DT | 1 |
| Bower, RR | 1 |
| Jarvis, KP | 1 |
| Ramer, NR | 1 |
| Shipkowitz, N | 1 |
| Bertrand, A | 1 |
| Janbon, F | 1 |
| Jourdan, J | 1 |
| Jonquet, O | 1 |
| Santoni, A | 1 |
| Muzzonigro, G | 1 |
| Caraceni, E | 1 |
| Baldassari, M | 1 |
| Ippoliti, L | 1 |
| Polito, M | 1 |
3 trials available for norfloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Interpretation of the bacteriologic outcome of antibiotic treatment for uncomplicated cystitis: impact of the definition of significant bacteriuria in a comparison of ritipenem acoxil with norfloxacin. Swedish Urinary Tract Infection Study Group.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteriuria; Cystitis; Data Interpretation, Statisti | 1995 |
[Combination of a 3d-generation cephalosporin (cefotaxime or ceftazidime) and a new quinolone (pefloxacine) in the treatment of febrile episodes in neutropenic diseases (37 cases)].
Topics: Agranulocytosis; Anti-Infective Agents; Cefotaxime; Ceftazidime; Drug Evaluation; Drug Therapy, Comb | 1987 |
Treatment of respiratory tract infections with pefloxacin in critically ill patients hospitalized in a surgical intensive care unit.
Topics: Bacterial Infections; Clinical Trials as Topic; Critical Care; Drug Resistance, Microbial; Humans; N | 1987 |
36 other studies available for norfloxacin and Infections, Pseudomonas
| Article | Year |
|---|---|
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Long | 2007 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, | 2008 |
Tandem Repeat of a Short Human Chemerin-Derived Peptide and Its Nontoxic d-Lysine-Containing Enantiomer Display Broad-Spectrum Antimicrobial and Antitubercular Activities.
Topics: Animals; Antimicrobial Peptides; Antitubercular Agents; Cell Survival; Chemokines; Dose-Response Rel | 2021 |
Otodectic and bacterial etiology of feline otitis externa in Tripoli, Libya.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Female; Gentamicins; Libya; Male; Mite Infestati | 2021 |
Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa.
Topics: Adult; Animals; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Fimbriae, Bacterial | 2012 |
Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
Topics: Anti-Infective Agents, Urinary; Drug Resistance, Microbial; Escherichia coli Infections; Humans; In | 1984 |
The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Female; Humans; Male; Microbial Sensiti | 1984 |
Norfloxacin and silver norfloxacin in the treatment of Pseudomonas corneal ulcer in the rabbit.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Corneal Ulcer; Drug Evaluati | 1984 |
Sulfadiazine silver-resistant Pseudomonas in Burns. New topical agents.
Topics: Administration, Topical; Animals; Burns; Drug Resistance, Microbial; Female; In Vitro Techniques; Mi | 1981 |
Norfloxacin nicotinate in the treatment of Pseudomonas aeruginosa infection in the genital tract of a bull.
Topics: Animals; Anti-Infective Agents; Cattle; Cattle Diseases; Drug Administration Schedule; Fluoroquinolo | 1994 |
Effects of ciprofloxacin, norfloxacin, and ofloxacin on in vitro adhesion and survival of Pseudomonas aeruginosa AK1 on urinary catheters.
Topics: Anti-Infective Agents; Bacterial Adhesion; Biofilms; Chromatography, High Pressure Liquid; Ciproflox | 1994 |
[Comparison of topical therapeutic effect between silver norfloxacin (Ag-NFL) and silver sulfadiazine (Ag-SD) in treatment of pyocyaneous sepsis in burn rats].
Topics: Administration, Topical; Animals; Anti-Infective Agents; Burns; Female; Fluoroquinolones; Male; Norf | 1993 |
[Combination effect of fosfomycin otic solution and norfloxacin against chronic otitis media].
Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Anti-Infective Agents; Chronic | 1999 |
Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Topics: Adult; Anti-Infective Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; Ciprofloxacin; | 2000 |
[The activity of four fluoroquinolones against strains of Pseudomonas aeruginosa with a different sensitivity pattern to ceftazidime and imipenem].
Topics: 4-Quinolones; Anti-Infective Agents; Ceftazidime; Ciprofloxacin; Drug Resistance; Fluoroquinolones; | 2001 |
Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
Topics: Anti-Infective Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Huma | 1992 |
Inducible beta-lactamases in clinical isolates of non-aeruginosa Pseudomonas.
Topics: beta-Lactamases; Cefazolin; Chloromercuribenzoates; Ciprofloxacin; Clavulanic Acids; Cloxacillin; Do | 1992 |
[Corneal ulcer. Current analysis from specialized ambulatory care of a clinic].
Topics: Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Contact Lenses, Extended-Wear; Corneal | 1992 |
The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis.
Topics: Administration, Topical; Animals; Ciprofloxacin; Colony Count, Microbial; Keratitis; Norfloxacin; Ps | 1991 |
Otitis externa malignum.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Diabetes Complications; Female; Humans; Male; Norflo | 1991 |
Topical norfloxacin therapy in Pseudomonas corneal ulceration.
Topics: Administration, Topical; Adolescent; Adult; Child; Cornea; Corneal Ulcer; Eye Infections, Bacterial; | 1991 |
The efficacy of norfloxacin in the treatment of chronic bacterial prostatitis refractory to trimethoprim-sulfamethoxazole and/or carbenicillin.
Topics: Carbenicillin; Chronic Disease; Escherichia coli Infections; Follow-Up Studies; Humans; Male; Middle | 1990 |
Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis.
Topics: Anti-Infective Agents; Antibodies, Monoclonal; Bacterial Outer Membrane Proteins; Culture Media; DNA | 1989 |
[New oral quinolone compounds in chronic bronchitis].
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Chronic Disease; Cipr | 1986 |
New 4-quinolones in the treatment of urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Combinations; Humans; Male; Norfloxacin; Pefloxa | 1986 |
Combination therapy: a way to limit emergence of resistance?
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftriaxone; Drug Resistance, Microbial; Drug Therapy, Com | 1986 |
Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.
Topics: Animals; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Mice; Mice, I | 1987 |
Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Drug Resistance, Microbial; Drug Therapy, Com | 1988 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Development of Pseudomonas aeruginosa resistance to norfloxacin during therapy.
Topics: Aged; Drug Resistance, Microbial; Humans; Male; Norfloxacin; Pseudomonas aeruginosa; Pseudomonas Inf | 1988 |
[The effect of pyridonic acid derivatives as topical antibiotics on the prevention and treatment of pyocyaneous infection following burn].
Topics: Administration, Topical; Animals; Burns; Male; Mice; Norfloxacin; Pseudomonas Infections; Rabbits; S | 1987 |
Treatment of perichondritis with a quinolone derivative--norfloxacin.
Topics: Carcinoma, Basal Cell; Cartilage Diseases; Ear Cartilage; Ear Neoplasms; Ear, External; Humans; Infl | 1988 |
Norfloxacin treatment in complicated urinary tract infection.
Topics: Adolescent; Adult; Aged; Bacteriuria; Child; Enterobacteriaceae Infections; Female; Humans; Male; Mi | 1986 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |
[Pefloxacin: clinical experience].
Topics: Acinetobacter Infections; Adult; Aged; Bacterial Infections; Enterobacteriaceae Infections; Enteroco | 1985 |
Norfloxacin treatment in urinary tract infections by urease-producing bacteria accompanying renal calculi. Our experience.
Topics: Adult; Female; Humans; Kidney Calculi; Male; Middle Aged; Norfloxacin; Proteus; Proteus Infections; | 1985 |